Danisco US Inc. was founded in 2005. The company’s line of business includes the manufacturing of in vitro and in vivo diagnostic substances.
In India, the Pharmaceutical business of Danisco US Inc is focused on Fungal production system, Stabilization of biomimetic membranes, Compositions and methods for clostridial transformation, Compositions and methods for clostridial transformation.
Danisco US Inc filed patent application numbered 7865/DELNP/2010 that is titled GEOBACILLUS STEAROTHERMOPHILUS ALPHA-AMYLASE (AMYS) VARIANTS WITH IMPROVED PROPERTIES. This Patent Application has been granted as as Patent number 317012.
The invention covers Electrical compound. The invention describes variants of a parent alpha-amylase that exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: specific activity, substrate specificity, substrate binding, substrate cleavage, thermal stability, pH-dependent activity, pH-dependent stability, oxidative stability, calcium dependency, pI, and wash performance. The variants are suitable for starch conversion, ethanol production, laundry washing, dish washing, hard surface cleaning, textile desizing, and/or sweetener production.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act that Claims 1-17 recite “variant polypeptide having a-amylase activity”, which is a new form of a known substance, as the said polypeptide having a-amylase activity very well known in the prior art which discloses polypeptide having a-amylase activity. The claimed variant of the known polypeptide is considered as a new form of a known substance.
As a response to said objection, the applicant submits that :
1. a novel substance, namely, novel polypeptides having alpha amylase activity
2.None of the documents cited by the Learned Controller disclose, teach or suggest the alpha amylases of the present application.
3.Furthermore, the alpha-amylases claimed by the present application show improved thermostability, liquidation performance which is not demonstrated by the amylases described in document D1. Therefore, the alpha-amylase claimed in the present application demonstrates new properties not exhibited by the prior art.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
